[Neurological manifestations in patients with severe COVID-19 in a tertiary care center].

Autor: Albarran-Sanchez A; Instituto Mexicano de Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio Medicina Interna. Ciudad de México, México., Noyola-García ME; Instituto Mexicano de Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio Medicina Interna. Ciudad de México, México., Calderón-Vallejo A; Instituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio de Neurología. Ciudad de México, México., Guízar-García LA; Instituto Mexicano de Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio Medicina Interna. Ciudad de México, México., Rosales-Dueñas FJ; Instituto Mexicano de Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio Medicina Interna. Ciudad de México, México., Barrientos-Flores CJ; Instituto Mexicano de Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio Medicina Interna. Ciudad de México, México., Segura-Mendez NH; Instituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Servicio de Inmunología y Alergia. Ciudad de México, México., Herrera-Sánchez DA; Instituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Dirección. Ciudad de México, México., Cuevas-García C; Instituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades 'Dr. Bernardo Sepúlveda Gutiérrez', Dirección. Ciudad de México, México.
Jazyk: Spanish; Castilian
Zdroj: Revista medica del Instituto Mexicano del Seguro Social [Rev Med Inst Mex Seguro Soc] 2021 Nov 01; Vol. 59 (6), pp. 545-550. Date of Electronic Publication: 2021 Nov 01.
Abstrakt: Background: The SARS-CoV-2 disease, called COVID-19, emerged in China has acquired pandemic dimensions. According to the WHO situational report of March 15, 2021, the global fatality rate is 2.2%; in Mexico, around 194 944 deaths have been confirmed by COVID-19. Studies in China identified that patients with severe COVID-19, when compared with those who had non-severe COVID-19, presented more severe neurological manifestations.
Objective: To determine the frequency of neurological symptoms and manifestations in patients with severe COVID-19 in a tertiary care center.
Material and Methods: A cross-sectional, observational and analytical study was carried out at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI, in patients hospitalized with severe COVID-19.
Results: 183 cases were analyzed, of which 130 were men (71%). The median age was 55 years (IQR: 44-65). The neurological symptoms were: headache, anosmia and dysgeusia. Neurological manifestations occurred in 27 patients (16%), the most frequent was ischemic-type cerebrovascular disease (CVD) in 12 (44%), in patients older than 76.5 years vs. 54 years (p = 0.000), with history of cardiovascular disease.
Conclusions: The most frequent neurological symptoms were headache, anosmia and dysgeusia. The most frequent neurological manifestation was ischemic CVD that appeared in older patients with severe COVID-19 with a history of cardiovascular disease.
(© 2021 Instituto Mexicano del Seguro Social.)
Databáze: MEDLINE
Externí odkaz: